Clinical Pharmacokinetics and Pharmacodynamics of Finasteride

January 1996 in “ Clinical Pharmacokinectics ”

Joseph P. Steiner

finasteride 5α-reductase dihydrotestosterone DHT male pattern baldness hair regrowth benign prostatic hyperplasia BPH loss of libido sexual potency Propecia testosterone

Studysummary Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

This document from 1996 discusses the pharmacokinetics and pharmacodynamics of finasteride, a drug used to treat benign prostatic hyperplasia (BPH) and male pattern baldness. Finasteride inhibits the enzyme 5α-reductase, which is responsible for converting testosterone to dihydrotestosterone (DHT). By inhibiting this enzyme, finasteride reduces the amount of DHT in the body, which can lead to hair regrowth and a reduction in prostate size. The drug is well-tolerated, with loss of libido and sexual potency being the most commonly reported adverse reactions. The document also discusses the different types of 5α-reductase isoenzymes and their roles in male sexual development.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

15 / 15 results

research Pharmacodynamic Modeling of Finasteride, a 5 Alpha-Reductase Inhibitor

7 citations , July 1995 in “PubMed”

Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.

research Inhibition of Steroid 5 Alpha-Reductase with Finasteride: Sleep-Related Erections, Potency, and Libido in Healthy Men

15 citations , June 1995 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that finasteride significantly reduced dihydrotestosterone levels but did not provide clear evidence of impaired libido or erectile function compared to placebo in men.

research Finasteride-Induced Gynecomastia in a 62-Year-Old Man

15 citations , June 1995 in “The American Journal of the Medical Sciences”

This study describes a case where finasteride treatment for benign prostatic hypertrophy was associated with gynecomastia in a 62-year-old man, which resolved after the drug was discontinued.

Picogram Determination of Finasteride in Human Plasma and Semen by High-Performance Liquid Chromatography with Atmospheric-Pressure Chemical-Ionization Tandem Mass Spectrometry

research Picogram Determination of Finasteride in Human Plasma and Semen by High-Performance Liquid Chromatography with Atmospheric-Pressure Chemical-Ionization Tandem Mass Spectrometry

45 citations , August 1994 in “Journal of Chromatography B: Biomedical Sciences and Applications”

Method detects finasteride in plasma and semen with high sensitivity and accuracy.

research Effect of Finasteride on Adrenal Steroidogenesis in Men

5 citations , July 1994 in “PubMed”

This study found that finasteride administered for 28 days had no significant effect on adrenal steroidogenesis in healthy men, aside from inhibiting androstenedione metabolism.

research Finasteride, A Steroid 5α-Reductase Inhibitor, Does Not Affect the Oxidative Metabolism of Antipyrine

9 citations , October 1993 in “The Journal of Clinical Pharmacology”

Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.

research Finasteride

86 citations , July 1993 in “Drugs”

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

research Finasteride: A Slow-Binding 5-Alpha-Reductase Inhibitor

70 citations , June 1993 in “Biochemistry”

This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.

research Finasteride: A 5 Alpha-Reductase Inhibitor

12 citations , January 1993 in “PubMed”

This review discusses the pharmacology and clinical use of finasteride for benign prostatic hyperplasia and reports its effectiveness in reducing prostate size and symptoms, though success varies among patients.

research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia

1040 citations , October 1992 in “The New England Journal of Medicine”

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

research Effects of Long-Term Treatment With Finasteride (MK-906), a 5-Alpha Reductase Inhibitor, on Circulating LH, FSH, Prolactin, and Estradiol

10 citations , October 1992 in “Hormone and Metabolic Research”

Finasteride safely lowers DHT levels without affecting hormone levels, helping with conditions like enlarged prostate, acne, and hair loss.

research Disposition and Pharmacokinetics of [14C]Finasteride After Oral Administration in Humans

17 citations , March 1992 in “PubMed”

This study reports that finasteride administered orally in humans is mainly metabolized through oxidative pathways, with most of the dose excreted as metabolites, primarily in the feces.

research High-Performance Liquid Chromatographic Method for the Determination of Finasteride in Human Plasma at Therapeutic Doses

19 citations , May 1991 in “Journal of Chromatography B: Biomedical Sciences and Applications”

This study developed and validated an HPLC method for detecting a novel 5α-reductase inhibitor in human plasma, supporting its pharmacokinetic evaluation at low doses.

research The Clinical Development of a 5α-Reductase Inhibitor, Finasteride

211 citations , November 1990 in “The Journal of Steroid Biochemistry and Molecular Biology”

Finasteride effectively treats BPH, but needs more trials to understand potential.

research Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers

147 citations , April 1990 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.